Company news
Caribou Biosciences, Inc. (NASDAQ:CRBU) news
Caribou Biosciences, Inc. news releases on 6ix. Latest, Oct 6, 2026: Caribou Biosciences to Evaluate Strategic Alternatives
Press releases & updates
Caribou Biosciences to Evaluate Strategic Alternatives
October 6, 2026
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 29, 2026
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
June 11, 2026
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
May 13, 2026
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
May 12, 2026
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
May 5, 2026
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
March 30, 2026
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 4, 2026
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample
February 17, 2026
Caribou Biosciences to Participate in Upcoming Investor Conferences
February 12, 2026
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
February 4, 2026
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
December 1, 2025
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
November 3, 2025
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
November 3, 2025
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
November 2, 2025
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
August 25, 2025
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
May 6, 2025
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
April 24, 2025
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 10, 2025
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
January 11, 2025
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer
January 1, 2025
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 5, 2024
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
September 24, 2024
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
September 2, 2024
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
August 11, 2024
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 5, 2024
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
July 8, 2024
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 1, 2024
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
May 29, 2024
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 6, 2024
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2024
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
April 14, 2024
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
April 3, 2024
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 10, 2024
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
March 4, 2024
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
January 6, 2024
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
December 11, 2023
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 6, 2023
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
November 5, 2023
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
October 17, 2023
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
September 26, 2023
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 7, 2023